NCT04136275

A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Study Summary

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. \- Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment

Want to learn more about this trial?

Request More Info

Interventions

CAR-37 T cellsBIOLOGICAL
CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells

Study Locations

FacilityCityStateCountry
Massachusetts General Hospital Cancer CenterBostonMassachusettsUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026